Medasense and Nihon Kohden Form Strategic Partnership

RAMAT GAN, Israel, June 26, 2024 -- Medasense, a prominent global leader in pain monitoring solutions, has announced a strategic partnership with Nihon Kohden for the exclusive distribution of its innovative pain monitoring device in Japan. This collaboration aims to revolutionize pain management practices across Japanese healthcare facilities, marking a significant advancement in patient care.

Nihon Kohden, known for its history of excellence in delivering high-quality, reliable medical technology, is teaming up with Medasense to bring its nociception monitor to the Japanese market. This advanced device, which features the state-of-the-art AI-powered NOL - Nociception Level Index®, offers real-time, objective pain monitoring. This technology allows for the personalization and optimization of pain treatment. The device will be available to hospitals and clinics throughout Japan via Nihon Kohden's extensive distribution networks, pending regulatory approval.

Medasense's CEO & Founder, Galit Zuckerman, expressed excitement about the partnership: "We are honored to partner with Nihon Kohden, a company with a long history of excellence, that shares our vision of improving patient care through innovative solutions. Our mission is to help all patients suffer less from pain and the adverse effects of pain medication. Nihon Kohden's established clinical, technological leadership and expertise in the Japanese market make them the perfect partner to distribute our nociception monitor."

NOL monitoring provides a clinically validated, AI-powered index that objectively quantifies the physiological response to pain (nociception). This aids clinicians in delivering personalized anesthesia tailored to individual patient needs. Over 40 peer-reviewed publications and clinical studies have demonstrated that NOL-guided analgesia can lead to reduced intraoperative opioid use, better postoperative pain scores, and improved patient recovery.

Medasense is at the forefront of transforming pain management with its breakthrough technology, which enables clinicians to optimize and personalize pain control, significantly reducing the risk of pain or overmedication. The company's flagship product, the PMD-200™, equipped with the NOL-Nociception Level Index®, harnesses advanced artificial intelligence and a proprietary non-invasive sensor system. This unique platform provides objective monitoring and quantification of a patient's pain response, making it an essential tool in operating rooms and critical care units where patients cannot communicate their pain levels. The PMD-200 is the first and only monitor authorized by the FDA for pain measurement in anesthesiology. It has been used in over 100,000 surgeries worldwide and is commercially available in the US, Europe, Canada, Latin America, and Israel.

Nihon Kohden, established in 1951, is a global leader in medical solutions, aiming to enhance healthcare through advanced technology. For over 70 years, Nihon Kohden has provided a wide range of medical electronic equipment, including EEG, EMG/EP measuring systems, electrocardiographs, bedside monitors, defibrillators, AEDs, ventilators, and hematology instruments. Utilizing cutting-edge technology, Nihon Kohden supports medical treatment in all clinical areas and integrates medical devices into IT networks to meet customer requirements, offering comprehensive solutions.

The partnership between Medasense and Nihon Kohden promises to bring significant improvements to pain management practices in Japan, enhancing the quality of patient care through innovative, high-tech solutions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!